April 3, 2024
You are here:  Home  >  Banking & Finance  >  Current Article

Arcutis reports Q1 loss, progress toward product launch


Arcutis Biotherapeutics beat analysts’ expectations in the first quarter with a smaller net loss than expected and a secure financial runway for its next few years of drug development. Arcutis, a pre-revenue biotechnology company in Westlake Village focused on treating skin diseases, had a net loss of $64.3 million, or $1.27 per share, in the…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.